Charme Capital Partners and EQT Private Equity to sell Igenomix to Vitrolife
- Igenomix is the worldwide leader in reproductive genetics and women’s health
- In 2019 Charme agreed to reinvest, as part of its sale to EQT, in a minority stake of the company to continue to support its development and international growth
- During its second stage of ownership, Igenomix has continued to grow rapidly taking advantage of multiple opportunities where Charme has been instrumental thanks to its knowledge of the company, its operations and management team
Charme Capital Partners (“Charme”), the pan-European mid-market private equity firm, has announced today that Charme III, its €650m buyout fund and EQT Private Equity (“EQT”), the publicly traded global investment firm founded by the Wallenberg family in the 90’s, have reached an agreement with Vitrolife, the Swedish publicly traded reproductive health company, to sell Igenomix. As part of the transaction Igenomix’s shareholders will retain a minority shareholder stake in Vitrolife.
Charme first invested in Igenomix in 2016 and since then it has actively worked together with the CEO David Jimenez and the R&D team composed of 25 top class scientists and researchers led by Professor Carlos Simon. In 2019 as part of the sale to EQT, Charme reinvested in a minority interest to continue supporting the development of the company with further international growth.
Leveraging its sector and company knowledge, Charme was instrumental in guiding the company through multiple growth opportunities to expand into new and attractive markets such as the establishment of Igenomix’s operations in China. The active involvement of Charme in this second stage of ownership, has led to a 19% compounded annual growth rate of revenues and a 17% compounded growth rate of EBITDA.
The combination of Igenomix and Vitrolife will create a global leader in the reproductive health space.
David Jimenez, Chief Executive Officer of Igenomix, said:
“Igenomix has been on a fantastic journey with EQT and Charme Capital Partners as owners. We are excited to embark on a new journey together with Vitrolife which will help us to further improve delivery of our mission to provide personalized genetic information to patients globally and further improve clinical practices in infertility, women’s health and rare diseases”.